EX-99.1 2 nrbo-20230922xex99d1.htm EX-99.1
Exhibit 99.1

| NeuroBo Pharmaceuticals, Inc. NASDAQ: NRBO September 2023

| 0.66” 0.66” 2 Forward Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may,—will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should,—continue,—could," "intend," "target," "predict," or the negative versions of those words or other comparable words or expressions, although not all forward-looking statements contain these identifying words or expressions. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements include statements regarding the market size and potential growth opportunities of NeuroBo’s current and future product candidates, capital requirements and use of proceeds, clinical development activities, the timeline for, and results of, clinical trials, regulatory submissions, and potential regulatory approval and commercialization of its current and future product candidates; executing on our commercial strategy, the realization of the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of our contract manufacturers, clinical study partners and others involved in the development of our current and future product candidates; initiating and completing clinical trials on a timely basis; recruiting subjects for our clinical trials; receiving results from our clinical trials that are consistent with the results of pre-clinical and previous clinical trials ;costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement and applicable laws or regulations. These forward-looking statements are based on information currently available to NeuroBo and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of NeuroBo's Annual Report on Form 10-K for the year ended December 31, 2022, and NeuroBo's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to this presentation. This presentation also may contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

| 0.66” 0.66” 3 Company is Reborn November 2022 • Licensed DA-1241 (GPR119) and DA-1726 (GLP1R/GCGR) • New focus: NASH and obesity • IND for DA-1241 Phase 2 filed and cleared by FDA Executing on Milestones • Initiation of DA-1241 Phase 2a clinical study • IND for DA-1726 Value Drivers in 2023 • Invested $15 million • Largest shareholder • NeuroBo has access to R&D, scientific, CMC expertise Dong-A is a Robust Partner Transformed Company: Compelling Investment Opportunity ➢ Transformed Company Through Licensing of Next Generation Cardiometabolic Assets Targeting Large NASH and Obesity Markets ➢ Well Capitalized Into 2024 ($28.9 million as of June 30, 2023) ➢ Multiple Near-Term Value Creating Milestones to Drive Shareholder Value

| 0.66” 0.66” 4 Committed Partner Provides Financial and R&D Support Dong-A Socio Group Revenue: $1.8B in 2022 Revenue $470M in 2022 Our strategic partner and largest shareholder, Dong-A ST Co. Ltd., is part of Dong-A Socio Group of companies established in 1932 and based in South Korea. The company has the full support of Dong-A ST’s R&D resources and Research Center which was established in 1977 as the first pharmaceutical research center in Korea. DONG-A ST Dong-A ST Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Stillen for the treatment of gastritis; Zydena for erectile dysfunction treatment; Motilitone for use in functional dyspepsia treatment; Sivextro an oxazolidinone class antibiotic; and Suganon for diabetes treatment. Dong-A Socio Holdings has been the leading pharmaceutical company in South Korea with its business focus in developing, manufacturing and distributing innovative products for the healthier life of their society.

| 0.66” 0.66” 5 Focused on Chronic Liver and Related Metabolic Diseases Product Preclinical Phase 1 Phase 2 Upcoming Catalysts DA-1241 (GPR119 Agonist) • 2H 2023: initiation of Part 2 of Phase 2a in NASH • 2H 2024: Phase 2a NASH data readout DA-1726 (GLP1R/GCGR Dual Agonist) • 2H 2023: Phase 1 IND submission • 1H 2024: Phase 1a data readout Completed Planned 2a 2b OBESITY NASH Ongoing

| 0.66” 0.66” 6 Multiple Near-Term Milestones: Driving Shareholder Value 2023 2024 1Q 2023 √ Phase 2a IND submitted and cleared 2H 2023 Phase 1 IND submission 2H 2024 Phase 1b data readout 2H 2024 Phase 2a NASH data readout DA-1726 DA-1241 1H 2024 Phase 2a Last patient last visit 3Q 2023 √ Phase 2a First patient in 1H 2024 Phase 1a data readout Corporate Opportunistic strategic partnerships Strategic divestiture Legacy assets The dates listed above are indicative only and are subject to receipt of FDA approval and enrollment into clinical trials, and delays of which may result in changes to the timing of the milestones set forth above. Investments in the current DA-1241 Phase 2a and planned DA-1726 Phase 1 have the potential for outsized returns in the event of clinical success

| DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of NASH

| 0.66” 0.66” 8 DA-1241: A Unique Mechanism of Action DA-1241 is a novel chemical entity activating G protein-coupled receptor 119 (GPR119) with clinically confirmed glucose-lowering activity & inflammation reduction ➢ GPR119 activation in hepatocytes, macrophages, and hepatic stellate cells inhibits lipid accumulation, immune cell infiltration, and the production of collagen fibers in the liver, directly ameliorating NASH pathophysiology such as steatosis, inflammation, and fibrosis. (1,2) ➢ DA-1241 effectively reduces BOTH hepatic and systemic inflammation in mice with NASH. (3) ➢ In T2D patients in the Phase 1b clinical trial, advanced clinical efficacy of DA-1241 monotherapy was successfully confirmed compared to previous GPR119 products which ceased development. Notes: GPR119 (G Protein-Coupled Receptor 119); NASH (Non-Alcoholic Steatohepatitis); GLP-1 (Glucagon-Like Peptide 1); 1. Dong-A Study Report 104458. 2. Park H et al. 80th Scientific Session of American Diabetes Association. 2020; Poster presentation 217-LB. 3. Park H et al. 80th Scientific Session of American Diabetes Association, 2020, Poster presentation 216-LB

| 0.66” 0.66” 9 DA-1241: Direct Effect on Innate Immune Cells Versus Current NASH Landscape The Highlights of DA-1241’s Anti-NASH Effects GPR119 GPR119 GPR119 DA-1421 Efruxifermin Lanifibranor Resmetirom Notes: TG (triglycerides); LDL-C (low density lipoprotein cholesterol); HDL-C (high density lipoprotein cholesterol); TNF (tumor necrosis factor CCL (CC motif chemokine ligand); CXCL (C※C motif chemokine ligand); FGF (fibrosis growth factor); PPAR (peroxisome proliferator-activated receptor); THR-B (thyroid hormone receptor beta) 1. Adopted and modified from Clinical Gastroenterology and Hepatology, 2023;21(8):2001-2014 MoA of the main candidate drugs for NASH1 Hepatic effects ➢ Reduces immune cell infiltration into the liver by inhibiting immune cell activation and differentiation ➢ Reduces collagen fiber deposition by inhibiting hepatic stellate cell activation ➢ Reduces liver fat accumulation by inhibiting lipid biosynthesis Extrahepatic effects ➢ Reduces fasted and postprandial glucose levels in humans ➢ Improve dyslipidemia (TG & LDL-C↓, HDL-C↑) ➢ Improve systemic inflammatory status such as TNF, CCL2, CXCL1/2/10`

| 0.66” 0.66” 10 DA-1241: Differentiated Anti-Inflammatory Effect (1-3) in NASH Mice DA-1241 was shown to effectively improve BOTH hepatic and systemic inflammation Combination with Sitagliptin potentiated the anti-inflammatory effect of DA-1241 monotherapy 38 100 84 68 58 103 0 20 40 60 80 100 120 Change in Plasma Inflammatory Cytokine & Chemokines after 8-week treatment in DIO-NASH mice (2,3) CCL2 (%) 27 100 58 68 44 91 0 20 40 60 80 100 120 TNFα (%) 40 100 77 75 51 94 0 20 40 60 80 100 120 CXCL10 (%) 1.2 4.5 3.0 2.5 2.1 3.9 0 1 2 3 4 5 Galectin-3-positive area (%) Notes: GPR119 (G Protein-Coupled Receptor 119); NASH (Non-Alcoholic Steatohepatitis); GLP-1 (Glucagon-Like Peptide 1); DA-1241 (L), 30 mg/kg/day; DA-1241 (H), 100 mg/kg/day; Elafibranor (PPARα/δ agonist with anti-inflammatory effects; discontinued in Phase 3 for NASH); Sitagliptin (JANUVIATM, approved DPP4 inhibitor for T2DM) 1. Dong-A Study Report 103420 2. Dong-A Study Report 104458. 3. Park H et al. 80th Scientific Session of American Diabetes Association, 2020, Poster presentation 216-LB Change in Hepatic Immune Cell Infiltration after 8-week treatment in DIO-NASH mice (1,3) 0.0 2.4 1.7 1.8 1.2 1.7 0 1 2 3 Inflammation score *Bold: p<0.05 vs. DIO-NASH

| 0.66” 0.66” 11 DA-1241: Pre-Clinical Highlights DA-1241 Encouraging Pre-Clinical Findings ➢ DA-1241 has a higher intrinsic activity compared to preexisting GPR119 agonists and triggers unique balanced signaling paths. Therefore, DA-1241 shows an improved in vivo efficacy with sustained anti-diabetic effects ➢ DA-1241 improved steatosis, inflammation and fibrosis in various NASH mouse models ➢ The combined use of DA-1241 and a DPP4 inhibitor augmented the anti-NASH effect as well as anti-diabetic effect ➢ DA-1241 showed no noteworthy safety concerns in safety pharmacology and toxicology studies up to 26 & 39-week chronic dosing in rats and dogs

| 0.66” 0.66” 12 Clinical Outcomes Study ▪ Phase 1a, First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose and Interactions with Metformin Study (n=60) ▪ Phase Ib, Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose Study (n=108) ➢ Study treated 24 healthy volunteers for 28 days and 84 subjects with T2DM for 56 days Safety/ PK ▪ Phase 1a, DA-1241 was well tolerated at doses up to 400 mg in healthy volunteers ▪ Phase 1b, DA-1241 was well tolerated at doses up to 200 mg/d for 28 days in healthy males and 100 mg/d for 56 days in T2DM subjects ▪ Once-daily oral administration of DA-1241 tablets showed sufficient clinical exposure, increasing in a dose-dependent manner in T2DM subjects. PD Results ▪ DA-1241 was comparable to Sitagliptin (JANUVIATM) in post-prandial glucose reduction, suggesting higher clinical efficacy than DS-8500a (Daiichi Sankyo’s GPR119 agonist; failed in Phase2b) ▪ Secretion of GIP, GLP-1 and PYY were increased at Day 56 in all DA-1241 treatment groups, consistent with the mechanism of action of DA-1241 Notes: T2DM (Type 2 Diabetes Mellitus); PK (Pharmacokinetics); PD (Pharmacodynamic); AE (Adverse Event); iAUE (incremental Area Under the Measurement Versus Time Curve); GLP-1 (Glucagon-Like Peptide 1); GIP (Glucose-Dependent Insulinotropic Peptide); PYY (Polypeptide YY). 1. Dong-A Study Report DA1241_DM_Ia. 2. Dong-A Study Report DA1241_DM_Ib. 3. Kim MK et al. 81st Meeting of the American Diabetes Association. 2021; Abstract 765-P. 4. Kim MK et al. 81st Meeting of the American Diabetes Association. 2021; Abstract 766-P. 5. 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin (NCT02647320) 34 18.5 -5.1 -38.6 -23.9 -45 -25 -5 15 35 55 Placebo DA-1241 25 mg DA-1241 50 mg DA-1241 100 mg Sitagliptin Change in Glucose iAUE0-4h in U.S. T2DM Subjects at Day 56 (Week 8) Confirmed enhanced efficacy of DA-1241: translation from non-clinical to clinical -24.16 -18.77 13.81 -5.51 -60 -53.4 -50 -40 -30 -20 -10 0 10 20 Placebo DS-8500a 25 mg DS-8500a 50 mg DS-8500a 75 mg Sitagliptin Change in Glucose iAUE0-3h in U.S. T2DM Subjects at Week 12 (5) DA-1241 Clinical Proof-of-Concept Phase 1 (1-4)

| 0.66” 0.66” 13 DA-1241: Ongoing Phase 2a in NASH Notes: FPFV (First Patient First Visit); LPO (Last Patient Last Visit) Study Design Study Overview: ▪ A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepatitis Primary Endpoint: ▪ Change from baseline in alanine transaminase (ALT) levels at Week 16 No. of Subjects: ▪ A total of 87 subjects, with a planned maximum of 98 subjects to account for early discontinuations Treatment Groups: ▪ 4 groups: DA-1241 50mg, DA-1241 100mg, DA-1241 100mg + Sitagliptin 100mg, Placebo Location: ▪ Approximately 20 centers in the United States Enrollment (planned): ▪ August 2023 ~ June 2024 ▪ DA-1241 alleviated progression of NASH in Ob-NASH mice on a high fat/fructose/CHO diet ▪ CCL2 and TIMP-1 and other biomarkers improved in both plasma and liver ▪ Reduced hepatic lipid and collagen deposition in the liver of NASH mice ▪ Effectively decreased hepatic inflammation ▪ Reduced systemic inflammation and fibrosis biomarkers Rationale for NASH study as monotherapy Rationale for Combination with DPP4 inhibitor

| 0.66” 0.66” 14 DA-1241: Potential for Best-In-Class Efficacy ▪ Novel, first-in-class GPR119 agonist for NASH ▪ Small molecule oral, once-daily administration ▪ Multimodal mechanism ▪ Proven preclinical anti-NASH effects ▪ Positive effects in animals on hepatic steatosis, fibrogenesis/fibrosis, hepatic & systemic inflammation, and NASH progression ▪ Promise in multiple co-morbidities: NASH, T2DM, dyslipidemia ▪ Decreased risk of hypoglycemia Promising Preclinical Efficacy In NASH ▪ Release of key peptides GLP-1, GIP, and PYY, which play a role in glucose & lipid metabolism, and weight loss ▪ Reduction of lipids, collagen deposition, and stellate cell activation ▪ Beneficial effects on blood glucose levels, as well as pro-inflammatory cytokines & chemokines ▪ Reversion of hepatic transcriptome toward normal control GPR119 Agonism Has Positive Effect On

| 0.66” 0.66” 15 DA-1241: Competitive Analysis Notes: 1. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3 Resmetirom DA-1241 Developer Madrigal NeuroBo Indication NASH NASH Status Phase 3 completion NDA Submitted Phase 2a IND approval Action THR(Thyroid hormone receptor) β agonist GPR119 agonist Dosage once daily, oral once daily, oral Efficacy in Human 1. NASH resolution with more than a 2-point reduction in NAS (100mg: 30%, 80mg: 26%, Placebo: 10%) To explore efficacy for NASH in Phase 2a. Confirmed comparable efficacy to Sitagliptin in Phase 1b for T2D, suggesting higher efficacy than DS-8500a. Safety in Human 1. mild/transient diarrhea, mild nausea To explore safety for NASH in Phase 2a Differentiation If approved by the NDA, the first treatment for NASH Concomitant control of hyperglycemia

| DA-1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity

| 0.66” 0.66” 17 DA-1726: Mechanism of Action DA-1726 is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of Obesity ➢ Oxyntomodulin is a gut hormone released from intestinal L-cells after meal ingestion and represents dual agonism of the GLP-1 receptor and glucagon receptor ➢ DA-1726 reduces food intake (GLP-1 R) and increases energy expenditure (GCGR) in humans, potentially resulting in superior body weight lowering ➢ DA-1726 is well balance to have low risk for hyperglycemia • While activation of GCGR increases glucose production posing a hyperglycemic risk, the simultaneous activation of GLP-1 receptor counteracts this effect Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); NASH (Non-Alcoholic Steatohepatitis); T2DM (Type 2 Diabetes Mellitus); OXM (Oxyntomodulin); GLP-1 (Glucagon-Like Peptide 1). 1. Pocai A. Mol Metab.2014;3:241-51. Physiological effects of oxyntomodulin (1)

| 0.66” 0.66” 18 5 7 9 11 13 15 17 19 21 6 12 18 24 30 36 42 48 54 60 66 72 Energy Expenditure (kcal/kg/hr) Time (hours) HF Control Pair-Fed DA-1726*# DA-1726: Mechanism of Action of Body Weight Loss (1,2) ▪ DA-1726 was superior to the pair-fed group in the body weight loss, indicating that reduced food intake via activating GLP-1 receptor and increase in energy expenditure, which is secondary to glucagon activation BWL in Obese Mice Cumulative Food Intake Energy Expenditure 4-week HFD feeding s.c. injection, every 3 days 14-week C57BL/6-DIO mouse 20-day ▪ Animals: male HF-DIO obese mice ▪ Regimen: Every three days S.C. injection ▪ DA-1726 Dose: 125 nmol/kg 58.1 41.6* 40.4* 0 20 40 60 80 HF Control DA-1726 Pair-Fed (40) (30) (20) (10) 0 10 0 3 6 9 12 15 18 Treatment Day HF-Control Pair-Fed DA-1726 % Change in BW from Baseline (Corrected to HF Control) Energy Expenditure for 72 Hours (kcal/kg/hr) Mean energy expenditure: DA-1726*# 16.6 kcal/kg/hr Pair-Fed 12.4 kcal/kg/hr HF Control 12.6 kcal/kg/hr (35.7%) (15.9%) # * Notes: HF-DIO (High Fat-Diet Induced Obesity); GLP-1 (Glucagon-Like Peptide 1); S.C. (Subcutaneous); HFD (High Fat Diet). 1. Dong-A Study Report 104372. 2. Kim TH et al. 82nd Meeting of the American Diabetes Association. 2022; Abstract 1403-P. * Statistically significant compared to control # Statistically significant compared to either treatment

| 0.66” 0.66” 19 DA-1726 :Therapeutic Potential in Obesity (1-3) – Semaglutide Comparison DA-1726 out-performed Semaglutide (WEGOVY™), a GLP-1 agonist, in mouse models of obesity BWL in HF-DIO Obese Mice DA-1726 vs Semaglutide (1,3) Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); HF-DIO (High Fat-Diet Induced Obesity); GLP-1 (Glucagon-Like Peptide 1). 1. Dong-A Study Report 104561. All treatments given as twice weekly injections. 2. Dong-A Study Report 104455. All treatments given every 3 days as injections. 3. Kim TH et al. 82nd Meeting of the American Diabetes Association. 2022; Abstract 1403-P. *Statistically significant compared to control % Change in BW from Baseline (Corrected to HF Control) -30 -25 -20 -15 -10 -5 0 0 2 4 6 8 10 12 14 16 19 21 25 27 Treatment Day High Fat Control Semaglutide (250 nmol/kg)* DA-1726 (100 nmol/kg)* DA-1726 (200 nmol/kg)* (16.3%) (19.3%) (26.8%) BWL in HF-FATZO T2DM/Obese Mice DA-1726 vs Semaglutide (2,3) % Change in BW from Baseline (Corrected to HF Control) -35 -30 -25 -20 -15 -10 -5 0 0 2 4 6 8 10 12 14 16 18 20 22 25 Treatment Day High Fat Control Semaglutide (250 nmol/kg)* DA-1726 (100 nmol/kg)* DA-1726 (250 nmol/kg)* (12.5%) (14.9%) (25.4%) Cumulative Food intake in HF-DIO Obese Mice DA-1726 vs Semaglutide (1,3) 100.0% 72.1% 86.7% 80.2% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 120.0% High Fat Control Semaglutide 250 nmol/kg* DA-1726 100 nmol/kg DA-1726 200 nmol/kg* Weight loss observed from DA-1726 is attributed to reduced food intake via GLP1R and increased energy expenditure via the GCGR

| 0.66” 0.66” 20 DA-1726: Therapeutic Potential in Obesity (1,2) – Tirzepatide Comparison DA-1726 shows similar efficacy while consuming more food compared to Tirzepatide (Mounjaro™) in mouse models of obesity and more effective in improving plasma metabolic parameters Cumulative Food intake in HF-DIO Obese Mice DA-1726 vs Tirzepatide (1,2) BWL in HF-DIO Obese Mice DA-1726 vs Tirzepatide (1,2) Plasma Biochemistry Analysis DA-1726 vs Tirzepatide (1,2) Notes: HF-DIO (High Fat-Diet Induced Obesity); BWL (Body Weight Loss) 1. Dong-A Study Report 105497. . All treatments given as twice weekly injections. 2. Jung I-H et al. 83rd Meeting of the American Diabetes Association. 2023; Abstract 1668-P. -40 -35 -30 -25 -20 -15 -10 -5 0 0 4 6 8 12 14 18 20 22 26 Treatment Day High Fat Control Tirzepatide (50 nmol/kg)* Tirzepatide (100 nmol/kg)* DA-1726 (100 nmol/kg)* DA-1726 (200 nmol/kg)* 100.0% 69.0% 58.0% 89.3% 78.4% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 120.0% High Fat Control Tirzepatide 50 nmol/kg* Tirzepatide 100 nmol/kg* DA-1726 100 nmol/kg* DA-1726 200 nmol/kg * * * * * * * * * * * * * * * 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 120.0% ALT AST T-BIL GLU T-CHO TG High Fat Control Tirzepatide 50 nmol/kg Tirzepatide 100 nmol/kg DA-1726 100 nmol/kg DA-1726 200 nmol/kg

| 0.66” 0.66” 21 GLP1R/GCGR dual agonist for the treatment of Obesity A novel oxyntomodulin analogue, once-weekly subcutaneous administration DA-1726: Pre-Clinical Highlights • DA-1726 induces balanced activation between GLP-1 and glucagon receptors • DA-1726 showed reduced food intake via activating GLP-1 receptor as well as energy expenditure via glucagon activation • In obese mouse, DA-1726 lost more weight than Semaglutide • In obese mouse, DA-1726 lost similar weight while consuming more food than Tirzepatide • Histopathology of DA-1726 showed further improvements in hepatic steatosis, inflammation, and fibrosis compared to Semaglutide • Balanced activation of GLP-1 and glucagon receptors potentially lowers the risk of hypoglycemia and hyperglycemia

| 0.66” 0.66” 22 DA-1726 Planned Phase 1a to Evaluate PK/PD and Safety in Obesity Notes: MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit). Phase I Study overview: ▪ 12-week SAD/MAD, PK/PD, safety and tolerability; extended dosing (12 weeks) in Phase I1b study with obese patients could provide an added clinical signal in obesity Population: ▪ Phase 1a: healthy volunteers; Phase 1b mix of healthy volunteers and otherwise healthy obese No. of Subjects: ▪ Approximately 100 subjects for both studies Location: ▪ United States (consideration may be given to Australia) Duration of Study: ▪ FPFV to topline results approximately 18 months (SAD & MAD combined) ▪ In animal models DA-1726 had superior weight loss compared with pair-fed group , indicating much of weight loss was attributed to reduced food intake via activation of GLP-1 ▪ DA-1726 was also superior to both the pair-fed and control groups in energy expenditure (secondary to glucagon activation) ▪ Potentially superior weight loss compared with Semaglutide ▪ Potential for similar weight loss while consuming more food than Tirzepatide Rationale for Obesity study

| 0.66” 0.66” 23 DA-1726: Competitive Differentiation Survodutide Mazdutide DA-1726 Semaglutide (Wegovy®) Tirzepatide (Maunjaro®) Developer Boehringer Ingelheim Innovent Biologics Lilly NeuroBo Novo Nordisk Lilly Indication Obesity Obesity Obesity Obesity Obesity Status Phase 2 completed Phase 3 (China) Phase 1 (USA) Phase 1 IND in 2H 2023 Marketed Phase 3 (Obesity) Marketed (T2D) Action glucagon/GLP-1 receptor dual agonist glucagon/GLP-1 receptor dual agonist GLP-1R(Glucagon-Like Peptide 1 receptor) & GCGR(Glucagon receptor) dual agonist GLP-1R(Glucagon-like peptide-1 receptor) agonist GLP-1R(Glucagon-like peptide-1 receptor) & GIPR(Glucose-dependent insulinotropic polypeptide receptor) dual agonist Dosage Survodutide 4.8mg, once weekly, injection Mazdutide 9mg, once weekly, injection To explore once weekly, injection in Phase 1 Semaglutide 2.4mg, once weekly, injection Tirzepatide 15mg, once weekly, injection Efficacy in Human Body weight loss, 16.7% @ 46-week Body weight loss, 15.4% @ 24-week (interim analysis) To explore efficacy in Phase 1b Body weight loss, 12.4% @ 68-week Body weight loss, 20.1% @ 72-week Safety in Human nausea, vomiting, diarrhea, constipation, Treatment discontinuations due to AEs: 28.6% nausea, diarrhea, vomiting, abdominal distension To explore safety in Phase 1b nausea, diarrhea, vomiting, constipation, abdominal pain nausea, diarrhea, decreased appetite, vomiting, constipation Differentiation First-in-class for obesity, Not reached plateau at week 46 No discontinued treatment due to adverse events in interim analysis Out-performed Semaglutide and similar efficacy to Tirzepatide in preclinical studies In clinical preparation for 7.2 mg dose in obesity and T2D patients, In recruiting participants for NASH P3 Higher efficacy

| Corporate Overview

| 0.66” 0.66” 25 Broad Intellectual Property Portfolio DA-1241 DA-1726 U.S. ▪ One patent: both composition of matter and process of making the composition - Expected to expire in 2035* ▪ One U.S. non-provisional patent application: both composition of matter and use of the composition ▪ One U.S. patent: both composition of matter and use of the composition - Expected to expire in 2038* ▪ One U.S. non-provisional patent application: both composition of matter and use of the composition ▪ PCT application entered national phases in October 2022 OUS ▪ 17 patents: - Expected to expire between 2035 and 2039* ▪ 14 patent applications: composition of matter and/or use of the composition ▪ 5 composition of matter patents: - Expected to expire between 2038 and 2040* ▪ 8 patent applications: composition of matter and/or use

| 0.66” 0.66” 26 Strong Leadership Team Management Team Hyung Heon Kim, Chief Executive Officer ▪ 35+ years on the pharmaceutical and biotech development ▪ Sr. director of clinical operations in Adiso therapeutics ▪ Director of clinical operations in Shire/Takeda pharmaceuticals ▪ Director of experimental trial management in AstraZeneca Robert Homolka, SVP Clinical Operations ▪ Visiting Professor, Hepatology, Oxford University ▪ NASH/NAFLD clinical trials expert, ~300 peer reviewed publications ▪ MD University of Mississippi ▪ Col (ret.) USA, MC Stephen Harrison, M.D., Consulting Medical Director ▪ 18+ years on pharmaceutical industry in Dong-A ST ▪ Team lead of corporate planning ▪ Study manager of clinical trials specialized in diabetes ▪ Manager of business development Sung-Jin Kim, Pharmacist, Director of Corporate Strategy ▪ 35+ years of investment banking and C-Suite experience ▪ CFO of Pinetree Therapeutics, US Medical Innovations, Rotor Clip ▪ Investment Banking positions at Credit Suisse, Prudential Securities, Chase, Citi ▪ BA Harvard University, MBA Columbia University Bennett Goldstein, Financial Advisor ▪ 25+ years in drug discovery research in Dong-A ST ▪ Specialized in diabetes, obesity, NASH, immune-mediated diseases ▪ Ph.D, RPh, College of Pharmacy, Ewha Womans University Mi-Kyung Kim, Ph.D, RPh, Chief Scientific Officer ▪ Bachelor’s degree in accounting from the George Washington University and is a licensed CPA Adam Perlish, CPA, Controller ▪ 20+ years of experience in M&A, financing and corporate governance ▪ 10+ years of licensing, M&A and compliance with Dong-A Group ▪ Former General Counsel/SVP at Dong-A ST and Dong-A Socio Group ▪ BA Soonghsil University, JD Washington University School of Law

| 0.66” 0.66” 27 Experienced Board of Directors ▪ 20+ years in executive management, at various levels ▪ Executive Vice President and General Counsel at Medifast Inc. ▪ U.S. Army Veteran; direct-commissioned Judge Advocate in U.S. Army’s (JAG) Corps. ▪ BS Bethune-Cookman University, J.D. North Carolina Central University Jason Groves ▪ 30+ years of experience in the pharmaceutical and medical device industry ▪ Former Co-Chief Executive Officer, TherapeuticsMD ▪ BA State University of New York, MBA NYU Stern School of Business Mark A. Glickman ▪ 35+ years of experience as C-suite executive and board member with public and private companies ▪ Former Chairman at Ampex Corporation ▪ BA Yale, MBA Wharton School of Finance D. Gordon Strickland - Chair of the Audit Committee ▪ 20+ years of experience in M&A, financing and corporate governance ▪ 10+ years of licensing, M&A and compliance with Dong-A Group ▪ Former General Counsel/SVP at Dong-A ST and Dong-A Socio Group ▪ BA Soonghsil University, JD Washington University School of Law Hyung Heon Kim - NeuroBo President & CEO ▪ 30+ years of experience as senior executive with public and private companies and private law practice ▪ Advisory Board for Olympusat, legal advisor to Current Health Inc. and Triage Technologies, Inc. ▪ BA Dartmouth College, J.D. and MBA University of Virginia Michael Salsbury – Chair of Compensation Committee Andrew Koven - Chairman of the Board, Chair of Nominating and Corporate Governance Committee ▪ 35+ years of experience as C-suite executive, board member and general counsel for public and private pharmaceutical companies ▪ Lead Independent Director of Kala Pharmaceuticals, Inc. ▪ BA and LLB Dalhousie University, LLM Columbia University

| 0.66” 0.66” 28 Supported By Scientific Advisory Board Scientific Advisory Board ▪ Prof. of Neurology, Harvard Medical School ▪ Director, Center for Autonomic and Peripheral Nerve Disorders ▪ Boston, MA Roy Freeman, MBChB ▪ Associate Prof. of Medicine, Colorado University School of Medicine ▪ Division of Endocrinology, Metabolism and Diabetes ▪ Boulder, CO Leigh Perreault, MD, FACE, FACP ▪ Associate Prof. of Medicine, Harvard Medical School ▪ Co-Director Center for Weight Management and Wellness Brigham and Women’s Hospital ▪ Boston, MA Caroline Apovian, MD, FACP, FTOS, DABOM ▪ University of California at San Diego ▪ Director, NAFLD Research Center, Director of Hepatology, Professor of Medicine, Vice Chief, Division of Gastroenterology ▪ San Diego, CA Rohit Loomba, MD, MHSc

| 0.66” 0.66” 29 Financials and Capitalization Table 1. No ratchets, price resets or anti-dilution provisions. Presumes $0 exercise price for each warrant exchangeable for one share of common stock. Financial Overview As of June 30, 2023 Cash $28.9 million Debt none Capitalization as of June 30, 2023 Common Stock Equivalents Common Stock 38,241,685 Warrants (WAEP $13.00)(1) 2,458,576 Options (WAEP $59.51) 40,272 Common Stock Shares Available for Issuance under Equity Incentive Plans 5,087,821 Fully Diluted 45,828,254

| 0.66” 0.66” 30 Compelling Investment Summary Targeting NASH and Obesity With a Pipeline of Next Generation Therapeutics • Driving Shareholder Value though Multiple, Near-Term, Value Creating Milestones ✓ IND Submission for Phase 2a Trial of DA-1241 for the Treatment of NASH ✓ Initiation of Phase 2a for DA-1241 in NASH • Submission of IND for DA-1726 in Obesity • Backed by Financial and Clinical Partner, Dong-A ST • Well Capitalized With $28.9 million in Cash at Q2 2023 • Exploring Strategic Opportunities to Out-License Legacy Assets

| THANK YOU! INVESTOR CONTACT: RX COMMUNICATIONS GROUP MICHAEL MILLER +1-917-633-6086 MMILLER@RXIR.COM

| Appendix

| 0.66” 0.66” 33 Opportunity and Challenge in NASH Select NASH Comparables in Phase 2(3) Company Drug Target Dev. Stage Akero Efruxifermin FGF-21 Phase 2 ongoing Altimmune Pemvidutide GLP-1 Phase 2b mid-2023 CytoDyn Leronlimab CCR5 Phase 2b planned Galectin Belapectin Galectin-3 Phase 2b planned NGM Pharm. MK-3655 β-Klotho/FGFR1c Phase 2b ended Terns Pharm. TERN-501 THRβ Phase 2b/3 2024 Viking Therap. VK2809 THRβ Phase 2 ▪ No FDA approved treatments for NASH ▪ Projected to grow to $160 billion by 2030(1) ▪ 60% increase in prevalence from 17 million to 27 million (2015-2030)(2) [ Essential Requirement and Demand ] high level of safety and proven effectiveness (1) https://www.globenewswire.com/news-release/2023/04/14/2647029/0/en/Global-Non-alcoholic-Steatohepatitis-NASH-Market-to-Reach-160-7-Billion-by-2030.html (2) Hepatology, Loomba, Sanyal, 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1. (3) NASDAQ, company websites & investor presentations GLOBAL NASH SALES 2022-2030(1) NASH Prevalence 2015-2030 (est.) (2) (est.) SELECT NASH COMPANIES COMPARABLES Market Cap(3) 0 5 10 15 20 25 30 35 40 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 U.S. NASH Prevalence (millions) 0 25 50 75 100 125 150 175 200 2022 2023 2024 2025 2026 2027 2028 2029 2030 Global NASH Sales ($billions) NRBO GALT ALT CYDY NGM TERN AKRO VKTX 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 Market Cap ($millions)

| 0.66” 0.66” 34 Tangible Universe of Successful, Early-Stage Comparables in Obesity Select Obesity Comparables in Phase 2 Company Drug Target Dev. Stage Altimmune Pemvidutide GLP/GCGR Phase 2 Hanmi Pharmaceuticals Efinopegdutide GLP/GCGR Phase 2 Jiangsu Hansoh Noliglutide GLP1 analog Phase 2 Rhythm Setmelanotide MC4R agonist Phase 2 Viking VK2735 GLP1/GIP (agonist) Phase 1 completed Zealand Pharma ZP6590 GIPR Preclinical ▪ Significant opportunity in obesity despite crowded landscape ▪ The obesity market is projected to grow to $54 billion by 2030(1) ▪ By 2030, 49% of U.S. adults are expected to be obese(2) GLOBAL OBESITY SALES 2022-2030(1) (est.) (1) https://www.morganstanley.com/ideas/obesity-drugs-investment-opportunity, accessed 4/26/2023 (2) https://www.latimes.com/science/story/2019-12-18/nearly-half-of-us-adults-will-be-obese-by-2030, accessed 4/20/2023 SELECT OBESITY COMPANY COMPARABLES Market Cap ($millioms) U.S. OBESITY PREVALENCE 2022-2030(2) (est.) 0 25 50 75 100 125 150 175 200 2022 2023 2024 2025 2026 2027 2028 2029 2030 U.S. NASH Prevalence (millions) 0 10 20 30 40 50 60 70 2022 2023 2024 2025 2026 2027 2028 2029 2030 Global Obesity Sales ($billions) - 500 1,000 1,500 2,000 2,500 NRBO ALT Rhythm VKTX Hamni Pharma Zealand